Telescope Innovations Corp. (TELIF)
USD 0.2
(2.36%)
USD 0.2
(2.36%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -718.09 Thousand CAD | 87.5% |
| 2022 | -5.74 Million CAD | -42.77% |
| 2021 | -4.02 Million CAD | -1491.18% |
| 2020 | -252.97 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 215 Thousand CAD | 140.8% |
| 2023 Q2 | 11.31 Thousand CAD | 104.19% |
| 2023 Q1 | -270.23 Thousand CAD | 63.76% |
| 2023 FY | -718.09 Thousand CAD | 87.5% |
| 2023 Q4 | -527.02 Thousand CAD | -876.78% |
| 2023 Q3 | 67.84 Thousand CAD | 499.67% |
| 2022 Q4 | -745.7 Thousand CAD | 24.7% |
| 2022 Q3 | -990.24 Thousand CAD | 69.24% |
| 2022 Q2 | -3.21 Million CAD | -306.26% |
| 2022 Q1 | -792.29 Thousand CAD | -42.55% |
| 2022 FY | -5.74 Million CAD | -42.77% |
| 2021 Q3 | -3.29 Million CAD | -2150.02% |
| 2021 FY | -4.02 Million CAD | -1491.18% |
| 2021 Q4 | -555.78 Thousand CAD | 83.13% |
| 2021 Q2 | 160.73 Thousand CAD | 514.48% |
| 2021 Q1 | -38.78 Thousand CAD | -13.37% |
| 2020 Q4 | -34.2 Thousand CAD | 0.0% |
| 2020 Q2 | -34.91 Thousand CAD | 0.0% |
| 2020 FY | -252.97 Thousand CAD | 0.0% |
| 2019 Q4 | -40.36 Thousand CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.17 Million USD | 77.357% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 80.646% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 69.839% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 101.355% |
| GB Sciences, Inc. | -1.36 Million USD | 47.264% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 76.27% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -214.778% |
| Skye Bioscience, Inc. | -37.64 Million USD | 98.092% |
| Zenith Capital Corp. | -10.59 Million USD | 93.223% |
| Agentix Corp. | -1.37 Million USD | 47.745% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 89.716% |
| Biomind Labs Inc. | -1.21 Million USD | 40.864% |
| ContraFect Corporation | -65.15 Million USD | 98.898% |
| CSL Limited | 2.64 Billion USD | 100.027% |
| CytoDyn Inc. | -49.84 Million USD | 98.559% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 63.16% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -13.549% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.853% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -72.835% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 60.556% |
| Regen BioPharma, Inc. | 1.02 Million USD | 170.16% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.103% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.096% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 66.905% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.042% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 75.173% |
| Mesoblast Limited | -87.95 Million USD | 99.184% |
| Marizyme, Inc. | -65.34 Million USD | 98.901% |
| Genus plc | 7.9 Million USD | 109.09% |
| Pharming Group N.V. | -10.54 Million USD | 93.192% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 91.88% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 58.431% |
| IMV Inc. | -36.48 Million USD | 98.032% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 91.09% |
| MultiCell Technologies, Inc. | -380.07 USD | -188837.301% |
| ONE Bio Corp. | 8.67 Million USD | 108.276% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 98.611% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 80.764% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 76.849% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 90.914% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -4694.965% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 95.476% |
| Alpha Cognition Inc. | -13.77 Million USD | 94.786% |
| Enzolytics Inc. | -2.17 Million USD | 67.012% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.757% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 832.749% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 110.37% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.248% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 89.08% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -162.651% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 82.68% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1088.099% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 64.187% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 93.407% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 85.303% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 80.833% |
| Helix BioMedix, Inc. | -1.05 Million USD | 32.002% |
| EV Biologics, Inc. | -1.26 Million USD | 43.329% |
| Q BioMed Inc. | -2.05 Million USD | 65.007% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 81.197% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 98.798% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 91.535% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 87.656% |
| HST Global, Inc. | -146.21 Thousand USD | -391.139% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 46.228% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 59.078% |
| Halberd Corporation | -79.67 Thousand USD | -801.268% |
| Resverlogix Corp. | -3.61 Million USD | 80.108% |
| Cell Source, Inc. | -5.32 Million USD | 86.505% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 81.926% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | 88.804% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -2989.639% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | 84.943% |
| Kadimastem Ltd | -3.3 Million USD | 78.288% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 83.836% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -62.697% |
| LadRx Corporation | 400.44 Thousand USD | 279.325% |
| Regen BioPharma, Inc. | 1.02 Million USD | 170.16% |
| Affymax, Inc. | -14.42 Million USD | 95.022% |
| Itoco Inc. | -1.86 Million USD | 61.579% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 56.975% |
| Mobile Lads Corp. | -2.26 Million USD | 68.272% |
| International Stem Cell Corporation | -131 Thousand USD | -448.163% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | 83.222% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -808.6% |
| Qrons Inc. | -789.34 Thousand USD | 9.027% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 23.731% |
| SYBLEU INC | -180.3 Thousand USD | -298.268% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 65.603% |
| Rebus Holdings, Inc. | -1.02 Million USD | 29.599% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 55.474% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -1223.139% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 71.62% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 98.506% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 66.032% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 8.041% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 77.333% |
| Neutra Corp. | -233.46 Thousand USD | -207.581% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 96.461% |
| PureTech Health plc | -65.69 Million USD | 98.907% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 96.623% |
| IXICO plc | -1.17 Million USD | 39.041% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 92.766% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 98.743% |
| CSL Limited | 2.64 Billion USD | 100.027% |
| Cellectis S.A. | -103.17 Million USD | 99.304% |